Matthew T. Chang

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index18.9kcitations154works0.62yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(23), Hippo pathway signaling and YAP/TAZ(23), Lung Cancer Treatments and Mutations(22), PI3K/AKT/mTOR signaling in cancer(14), Ubiquitin and proteasome pathways(13)

Publications153 total

Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
2024· 2 citedOpen Access
Author response: Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
2024Open Access
Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
2024· 1 citedOpen Access
Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
2024· 1 citedOpen Access
Reviewer #3 (Public Review): Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
2024Open Access
Reviewer #2 (Public Review): Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
2024Open Access
Reviewer #1 (Public Review): Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
2024Open Access
Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
2023Open Access
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
Nature Cancer·2023· 170 citedOpen Access
Supplementary Figure 1 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
2023Open Access
Data from Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways
2023Open Access
Figure S4 from Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways
2023Open Access
Data from Accelerating Discovery of Functional Mutant Alleles in Cancer
2023Open Access
Table S1-4 from Accelerating Discovery of Functional Mutant Alleles in Cancer
2023Open Access
Supplementary Table Captions from Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
2023Open Access
Supplementary Figure 3 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
2023Open Access
Figure S1 from Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways
2023Open Access
Supplementary Figure 4 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
2023Open Access
Supplementary Figure 4 from Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
2023Open Access
Table S3 from Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Barry S. Taylor(25), David B. Solit(18), David M. Hyman(13), Michael F. Berger(12), Nikolaus Schultz(11), Alexander Penson(10), José Baselga(10), Ahmet Zehir(9), Jianjiong Gao(9), Anwesha Dey(9), Philip Jonsson(8), Scott E. Martin(8), Alison M. Schram(7), Ritika Kundra(7), Pedram Razavi(7), Marc Ladanyi(7), Sarat Chandarlapaty(7), Mark T.A. Donoghue(7), Alexander N. Gorelick(7), Zora Modrušan(7)